1-异己基哌嗪 | 118157-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-异己基哌嗪
• 英文名称: 1-(4-Methylpentyl)piperazine
• CAS: 118157-08-7
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.3
• InChiKey: DNRRGRHYTDLXGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2015120049A1

  公开（公告）日：2015-08-13

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开了作为成纤维细胞生长因子抑制剂（FGFR）的化合物，因此可用于治疗可以通过抑制FGFR治疗的疾病。还公开了含有此类化合物的药物组合物以及制备此类化合物的过程。
• ARGINASE INHIBITORS AND METHODS OF USE
  申请人：CHRISTIANSON DAVID W.

  公开号：US20100189644A1

  公开（公告）日：2010-07-29

  The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

  本发明涉及化合物IA或化合物IB的抑制剂，或其药用盐，含有这些化合物的组合物，以及用于治疗和诊断由精氨酸酶上调、异常高的精氨酸酶活性或异常低的一氧化氮合酶活性所特征的疾病的方法。
• Chemokine Receptor Modulators
  申请人：Altiris Therapeutics, Inc

  公开号：US20130172330A1

  公开（公告）日：2013-07-04

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers

  本发明提供了化合物I式及其药学上可接受的盐、溶剂合物、互变异构体、立体异构体和/或酯类。这些化合物和包含这些化合物的药物组合物可用于治疗或预防HIV感染，并用于治疗增殖性疾病，如抑制各种癌症的转移。
• QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
  申请人：Principia Biopharma, Inc.

  公开号：US20160200725A1

  公开（公告）日：2016-07-14

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明公开了一种纤维母细胞生长因子抑制剂（FGFR），因此对于通过抑制FGFR可治疗的疾病具有用处的化合物。同时还公开了包含这种化合物的制药组合物以及制备这种化合物的方法。
• Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10301314B2

  公开（公告）日：2019-05-28

  The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

  本发明公开了用于降低细胞核周室流行率的化合物，例如，式（I）化合物，其中 R1、R2、R3 和 R4 如本文所定义，可用于治疗与细胞核周室流行率增加有关的疾病或紊乱，如癌症。还公开了一种含有药学上可接受的载体和至少一种体现本发明原理的化合物的组合物，以及一种治疗或预防哺乳动物癌症的方法。